CytoGenix Announces Completion of synDNA™ Production Module Prototype
News Dec 26, 2005
CytoGenix, Inc. has announced that the prototype version of the synDNA™ production module was completed on schedule.
The device was designed for the commercial production of cell-free DNA by the leading international biopharmaceutical plant design, engineering and construction firm of Alfa Laval Biokinetics, Philadelphia, Pennsylvania.
It was tested by Alfa Laval engineers and CytoGenix senior scientists. The final version will be mounted on a stainless steel cart and have the capacity to produce up to 10 grams of high-purity DNA in 24 hours.
Kurt Berens, CytoGenix, Inc. Vice President of Product Development, commented, "This is an important step in our overall plan to construct a cGMP manufacturing facility."
"We plan to install several synDNA™ production modules to meet the growing demand for clinical-grade DNA internally and from customers."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE